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Abstract
Introduction: Bone marrow mesenchymal stem cells (BMMSCs) are a heterogeneous population of postnatal
precursor cells with the capacity of adhering to culture dishes generating colony-forming unit-fibroblasts (CFU-F).
Here we identify a new subset of BMMSCs that fail to adhere to plastic culture dishes and remain in culture
suspension (S-BMMSCs).
Methods: To catch S-BMMSCs, we used BMMSCs-produced extracellular cell matrix (ECM)-coated dishes. Isolated
S-BMMSCs were analyzed by in vitro stem cell analysis approaches, including flow cytometry, inductive multiple
differentiation, western blot and in vivo implantation to assess the bone regeneration ability of S-BMMSCs.
Furthermore, we performed systemic S-BMMSCs transplantation to treat systemic lupus erythematosus (SLE)-like
MRL/lpr mice.
Results: S-BMMSCs are capable of adhering to ECM-coated dishes and showing mesenchymal stem cell
characteristics with distinction from hematopoietic cells as evidenced by co-expression of CD73 or Oct-4 with
CD34, forming a single colony cluster on ECM, and failure to differentiate into hematopoietic cell lineage.
Moreover, we found that culture-expanded S-BMMSCs exhibited significantly increased immunomodulatory
capacities in vitro and an efficacious treatment for SLE-like MRL/lpr mice by rebalancing regulatory T cells (Tregs)
and T helper 17 cells (Th17) through high NO production.
Conclusions: These data suggest that it is feasible to improve immunotherapy by identifying a new subset
BMMSCs.
Introduction
Bone marrow mesenchymal stem cells (BMMSCs) are
hierarchical postnatal stem/progenitor cells capable of
self-renewing and differentiating into osteoblasts, chon-
drocytes, adipocytes, and neural cells [1,2]. BMMSCs
express a unique surface molecule profile, including
expression of STRO-1, CD29, CD73, CD90, CD105,
CD146, Octamer-4 (Oct4), and stage-specific embryonic
antigen-4 (SSEA4) [3,4]. It is generally believed that
BMMSCs are negative for hematopoietic cell markers
such as CD14 and CD34 [5-13]. BMMSCs have been
widely used for tissue engineering [14-16]. Recently, a
growing body of evidence has indicated that BMMSCs
produce a variety of cytokines and display profound
immunomodulatory properties [17-19], perhaps by inhi-
biting the proliferation and function of several major
immune cells, such as natural killer cells, dendritic cells,
and T and B lymphocytes [17-20]. These unique proper-
ties make BMMSCs of great interest for clinical applica-
tions in the treatment of different immune disorders
[17,21-24].
BMMSCs are thought to be derived from the bone
marrow stromal compartment, initially appearing as
adherent, single colony clusters (colony-forming unit-
fibroblasts [CFU-F]), and subsequently proliferating on
culture dishes [25]. To date, the CFU-F assay has been
considered one of the gold standards for determining
the incidence of clonogenic BMMSC [26,27]. Since
BMMSC are a heterogeneous population of stem cells, it
is critical to identify whether BMMSC contain unique
cell subsets with distinctive functions, analogous to the
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hematopoietic stem/progenitor cell system. In this study,
we identified a subset of mouse BMMSCs in culture




Female C3H/HeJ, C57BL/6J, and C3MRL-Faslpr/J mice
were purchased from Jackson Laboratory (Bar Harbor,
ME, USA). Female immunocompromised mice (Beige
nude/nude XIDIII) were purchased from Harlan (India-
napolis, IN, USA). All animal experiments were per-
formed under the institutionally approved protocols for
the use of animal research (USC #10874 and 10941).
Antibodies
Anti Oct4, SSEA4, Runx2, OCN, active b catenin and b
catenin were purchased from Millipore (Billerica, MA,
USA). Anti alkaline phosphatase (ALP) antibody was
purchased from Abcam (Cambridge, MA, USA). Anti
Sca-1-PE, CD34-PE, CD34-FITC, CD45-PE, CD73-PE,
CD4-PerCP, CD8-FITC, CD25-APC, CD3ε and CD28
antibodies were purchased from BD Bioscience (San
Jose, CA, USA). Anti Foxp3-PE, IL17-PE, and IFNg-APC
antibodies were purchased from eBioscience (San Diego,
CA, USA). Unconjugated anti CD34, CD73, and CD105,
NOS2 were purchased from Santa Cruz Biosciences
(Santa Cruz, CA, USA). Anti b actin antibody was pur-
chased from Sigma (St. Louis, MO, USA).
Isolation of mouse bone marrow mesenchymal stem cells
(BMMSCs)
The single suspension of bone marrow derived all
nucleated cells (ANCs) from femurs and tibias were
seeded at a density of 15 × 106 into 100 mm culture
dishes (Corning, NY, USA) at 37°C and 5% CO2. Non-
adherent cells were removed after two days and attached
cells were maintained for 16 days in alpha minimum
essential medium (a-MEM, Invitrogen, Grand Island,
NY, USA) supplemented with 20% fetal bovine serum
(FBS, Equitech-bio, Kerrville, TX, USA), 2 mM L-gluta-
mine, 55 μM 2-mercaptoethanol, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Invitrogen). Colony-form-
ing attached cells were passed once for further experi-
mental use.
Preparation of Extracellular Matrix (ECM) coated dishes
ECM coated dishes were prepared as described pre-
viously [28]. Briefly, 100% confluence of BMMSCs was
cultured in medium with 100 nM L-ascorbic acid phos-
phate (Wako Pure Chemical, Richmond, VA, USA).
After two weeks, cultures were washed with PBS and
incubated with 0.005% Triton X-100 (Sigma) for 15
minutes at room temperature to remove cells. The ECM
was treated with DNase I (100 units/ml; Sigma) for 1
hour at 37°C. The ECM was washed with PBS three
times and stored in 2 ml of PBS containing 100 U/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml fun-
gizone (Invitrogen) at 4°C.
Isolation of BMMSCs in culture suspension (S-BMMSCs)
Bone marrow-derived ANCs (15 × 106) were seeded into
100 mm culture dishes and cultured for two days. The
culture supernatant with floating cells was collected and
centrifuged to obtain putative non-attached BMMSCs.
The cells were re-seeded at indicated numbers on ECM-
coated dishes. After 2 days, the floating cells in the cul-
tures were removed with PBS and the attached cells on
ECM were maintained for an additional 14 days. Col-
ony-forming attached cells were passed once and sub-
cultured on regular plastic culture dishes for further
experiments. For some stem cell characterization ana-
lyses, we collected SSEA4 positive S-BMMSCs using the
MACS magnetic separation system (Milteny Biotech,
Auburn, CA, USA) and expanded in the cultures.
Colony forming unit-fibroblastic (CFU-F) assay
One million cells of ANCs from bone marrow were
seeded on a T-25 cell culture flask (Nunc, Rochester,
NY, USA). After 16 days, the cultures were washed with
PBS and stained with 1% toluidine blue solution in 2%
paraformaldehyde (PFA). A cell cluster that had more
than 50 cells was counted as a colony under microscopy.
The colony number was counted in five independent
samples per each experimental group.
Cell proliferation assay
The proliferation of BMMSCs and S-BMMSCs was per-
formed using the bromodeoxyuridine (BrdU) incorpora-
tion assay. Each cell population (1 × 104 cells/well) was
seeded on two-well chamber slides (Nunc) and cultured
for two to three days. The cultures were incubated with
BrdU solution (1:100) (Invitrogen) for 20 hours, and
stained with a BrdU staining kit (Invitrogen). BrdU-posi-
tive and total cell numbers were counted in ten images
per subject. The BrdU assay was repeated in five inde-
pendent samples for each experimental group.
Population doubling assay
A total of 0.5 × 106 cells of BMMSCs and S-BMMSCs
was seeded on 60 mm culture dishes at the first passage.
Upon reaching confluence, the cells were passaged at
the same cell density. The population doubling was cal-
culated at every passage according to the equation: log2
(number of harvested cells/number of seeded cells). The
finite population doublings were determined by cumula-
tive addition of total numbers generated from each pas-
sage until the cells ceased dividing.
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Flow cytometric analysis of mesenchymal stem cell
surface molecules
BMMSCs or S-BMMSCs (0.2 × 106 cells) were incubated
with 1 µg of R-Phycoerythrin (PE). (PE)-conjugated anti-
bodies or isotype-matched control immunoglobulin Gs
(IgGs) (Southern Biotech, Birmingham, AL, USA) at 4°C
for 45 minutes. Samples were analyzed by a fluorescence-
activated cell sorting (FACS)Calibur flow cytometer (BD
Bioscience). For dual color analysis, the cells were treated
with PE-conjugated and fluorescein isothiocyanate
(FITC)-conjugated antibodies or isotype-matched control
IgGs (1 µg each). The cells were analyzed on FACSCalibur
(BD Bioscience).
Immunofluorescent microscopy
The cells subcultured on eight-well chamber slides
(Nunc) (2 × 103/well) were fixed with 4% PFA. The
samples were incubated with the specific or isotype-
matched mouse antibodies (1:200) overnight at 4°C, and
treated with Rhodamine-conjugated secondary antibo-
dies (1:400, Jackson ImmunoResearch, West Grove, PA,
USA; Southern Biotechnology, Birmingham, AL, USA).
Finally, chamber slides were mounted using Vectashield
mounting medium containing 4’, 6-diamidino-2-pheny-
lindole (DAPI) (Vector Laboratories, Burlingame, CA,
USA).
In vivo bone formation assay
A total of 4.0 × 106 cells was mixed with hydroxyapa-
tite/tricalcium phosphate (HA/TCP) ceramic powders
(40 mg, Zimmer Inc., Warsaw, IN, USA) and subcuta-
neously transplanted into eight-week-old immunocom-
promised mice. After eight weeks, the transplants were
harvested, fixed in 4% PFA and then decalcified with 5%
ethylenediaminetetraacetic acid (EDTA; pH 7.4), fol-
lowed by paraffin embedding. The paraffin sections were
stained with H & E and analyzed by an NIH Image-J.
The newly-formed mineralized tissue area from five
fields was calculated and shown as a percentage to total
tissue area.
In vitro osteogenic differentiation assay
BMMSCs and S-BMMSCs were cultured under osteogenic
culture conditions containing 2 mM b-glycerophosphate
(Sigma), 100 μM L-ascorbic acid 2-phosphate and 10 nM
dexamethasone (Sigma). After induction, the cultures were
stained with alizarin red or alkaline phosphatase.
In vitro adipogenic differentiation assay
For adipogenic induction, 500 nM isobutylmethyl-
xanthine, 60 μM indomethacin, 500 nM hydrocortisone,
10 μg/ml insulin (Sigma), 100 nM L-ascorbic acid phos-
phate were added to the culture medium. After 10 days,
the cultured cells were stained with Oil Red-O and
positive cells were quantified by using an NIH Image-J.
Total RNA was also isolated from cultures after 10 days
induction for further experiments.
In vitro chondrogenic differentiation assay
For chondrogenic induction, 1 × 106 cell pellets were cul-
tured under chondrogenic medium containing 15% FBS,
1% ITS (BD), 100 nM dexamethasone, 2 mM pyruvate
(SIGMA), and 10 ng/ml transforming growth factor beta
1 (TGFb1) in (D)MEM (Invitrogen) for threeweeks. Cell
pellets were harvested at three weeks post induction,
fixed overnight with 4% PFA and then, sections were pre-
pared for staining.
Reverse transcriptase polymerase chain reaction (RT-PCR)
analysis
Extraction of total RNA and RT-PCR were performed
according to standard procedures. Primer information is
described in Additional materials and methods [see
Additional file 1].
Western blotting analysis
A total of 20 µg of protein was used and SDS-PAGE and
western blotting were performed according to standard
procedures. Detailed procedures are described in Addi-
tional materials and methods [see Additional file 1]. b-actin
on the same membrane served as the loading control.
Hematopoietic differentiation of BMMSCs and S-BMMSCs
BMMSCs and S-BMMSCs were cultured onto 35 mm
low attach culture dishes (2 × 104/dish, STEMCELL
Technologies, Vancouver, BC, V5Z 1B3, Canada) under
hematopoietic differentiation medium (STEMCELL
Technologies) with or without erythropoietin (EPO; 3
U/mL) for seven days. Whole bone marrow cells and
linage negative bone marrow cells (Linage-cells) were
used as positive controls. The results are representative
of five independent experiments.
Inhibitor treatment
S-BMMSCs and BMMSCs were treated with 1 mM L-
NG-monomethyl-arginine (L-NMMA) (Cayman Chemi-
cal, Ann Arbor, MI, USA) or 0.2 mM 1400 W (Cayman
Chemical) to inhibit total nitric oxide synthase (NOS) or
inducible nitric oxide synthase (iNOS), respectively.
Measurement of nitric oxide production
BMMSCs (0.2 × 106/well) were cultured on 24-well plates
with or without cytokines (IFNg, 25 ng/ml; IL-1b, 5 ng/ml,
R&D Systems, Minneapolis, MN, USA) and chemicals
(L-NMMA, 1 mM; 1400 W, 0.2 mM) at the indicated con-
centration and days. The supernatant from each culture
was collected and nitric oxide concentration measured
using a Total Nitric Oxide and Nitrate/Nitrite Parameter
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Assay kit (R&D Systems) according to the manufacturer’s
instruction.
Cell apoptosis and cell survival assay
The transwell system (Corning) was used for co-culture
experiments. A total of 0.2 × 106 of S-BMMSCs or
BMMSCs was seeded on each lower chamber. Activated
spleen cells (1 × 106/chamber), which were pre-stimu-
lated with plate-bound anti CD3ε antibody (3 µg/ml)
and soluble anti CD28 antibody (2 µg/ml) for two days,
were loaded in the upper chambers. Both chambers
were filled with a complete medium containing (D)
MEM (Lonza, CH-4002 Basel, Switzerland) with 10%
heat-inactivated FBS, 50 µM 2-mercaptoethanol, 10 mM
HEPES, 1 mM sodium pyruvate (Sigma), 1% non-essen-
tial amino acid (Cambrex, East Rutherford, NJ, USA), 2
mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. To measure the spleen cells viability, cell
counting kit-8 (Dojindo Molecular Technologies, Rock-
ville, MD, USA) was used. For apoptosis of spleen cells
analyses, Annexin V-PE apoptosis detection kits I (BD
Bioscience) were used and analyzed on FACSCalibur (BD
Bioscience).
In vitro CD4+CD25+Foxp3+Tregs and Th17 induction
CD4+CD25- T-lymphocytes (1 × 106/well), collected
using a CD4+CD25+ Treg isolation kit (Miltenyi Biotec),
were pre-stimulated with plate-bound anti CD3ε anti-
body (3 µg/ml) and soluble anti CD28 antibody (2 µg/
ml) for two days. These activated T-lymphocytes were
loaded on 0.2 × 106 BMMSCs or S-BMMSCs cultures
with recombinant human TFGb1 (2 ng/ml) (R&D Sys-
tems) and recombinant mouse IL2 (2 ng/ml) (R&D Sys-
tems). For Th17 induction, recombinant human TFGb1
(2 ng/ml) and recombinant mouse IL6 (50 ng/ml) (Bio-
legend, San Diego, CA, USA) were added. After three
days, cells in suspension were collected and stained with
anti CD4-PerCP, anti CD8a-FITC, anti CD25-APC anti-
bodies (each 1 µg) for 45 minutes on ice under dark
conditions. The cells were then stained with anti Foxp3-
PE antibody (1 µg) using a Foxp3 staining buffer kit
(eBioscience) for cell fixation and permeabilization. For
Th17, cells in suspension were stained with anti CD4-
FITC (1µg, Biolegend) for 45 minutes on ice under dark
conditions followed by intercellular staining with anti-IL
17 antibody (1µg, Biolegend) using a Foxp3 staining buf-
fer kit. The cells were analyzed on FACSCalibur.
Allogenic mouse S-BMMSC transplantation into
MRL/lpr mice
Under general anesthesia, C3H/HeJ-derived BMMSCs,
S-BMMSCs, L-NMMA pre-treated BMMSCs (1 mM for
five days), or CD34+/CD73+ double sorted cells (0.1 ×
106 cells/10 g body weight) were infused into MRL/lpr
mice via the tail vein at 10 weeks of age (n = 6 each
group). In the control group, MRL/lpr mice received
PBS (n = 5). All mice were sacrificed at two weeks post
transplantation for further analysis. The protein concen-
tration in urine was measured using a Bio-Rad Protein
Assay (Bio-Rad, Hercules, CA, USA).
Measurement of autoantibodies, albumin, soluble runt-
related NF-B ligand (sRANKL) and C-terminal
telopeptides of type I collagen (CTX)
Peripheral blood serum samples were collected from
mice. Autoantibodies, sRANKL and CTX were analyzed
by ELISA using commercially available kits (anti-dsDNA
antibodies and ANA; alpha diagnostics, albumin and
sRANKL; R&D Systems, CTX; Nordic Bioscience Diag-
nostics, Herlev, Rigion Hovedstaden, Denmark) accord-
ing to their manufactures’ instructions. The results were
averaged in each group. The intra-group differences
were calculated between the mean values.
Flow cytometric analysis of Tregs and Th17 cells
To detect Tregs, peripheral blood mononuclear cells
(PBMNCs) (1 × 106) were treated with PerCP-conju-
gated anti-CD4, FITC-conjugated anti-CD8a, APC-conju-
gated anti-CD25 antibodies, and stained with R-PE-
conjugated anti-Foxp3 antibody using a Foxp3 staining
buffer kit (eBioscience). To measure Th17 cells, PBMNCs
(1 × 106) were incubated with PerCP-conjugated anti-
CD4, FITC-conjugated anti-CD8a, followed by treatment
with R-PE-conjugated anti-IL-17 and APC-conjugated
anti-IFNg antibodies using a Foxp3 staining buffer kit. The
cells were then analyzed on FACSCalibur .
Statistics
Student’s t-test was used to analyze statistical difference.
P values less than 0.05 were considered significant.
Results
A subset of BMMSCs lacks the ability to adhere to plastic
culture dishes (S-BMMSCs) but attaches to extracellular
cell matrix (ECM)-coated culture dishes
To determine whether a subset of BMMSCs remain in
culture suspension, ANCs (15 × 106 cells) from bone mar-
row were plated onto regular plastic culture dishes for two
days and all non-attached cells were subsequently trans-
planted into immunocompromised mice subcutaneously
using HA/TCP as a carrier. At eight weeks post-transplan-
tation, newly formed bone was identified in the transplants
by H & E staining (Figure 1A), suggesting that the
BMMSC culture suspension may contain cells with a
capacity to differentiate into bone forming cells. In vitro
studies indicated that ECM produced by culture-expanded
BMMSCs (BMMSC-ECM) could capture higher numbers
of CFU-Fs when compared to plastic cultures [see
Akiyama et al. Stem Cell Research & Therapy 2012, 3:40
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Additional file 1, Figure S1] [28]. Thus, we collected cul-
ture supernatant with floating cells at two days post CFU-
F culture and re-loaded it onto BMMSC-ECM-coated
dishes (Figure 1B). A subset of BMMSCs in the suspension
(S-BMMSCs) was able to adhere to the BMMSC-ECM
and form CFU-F (Figure 1B), at a lower incidence com-
pared to the number of CFU-F generated from regular
BMMSCs (Figure 1C). In order to characterize the stem
cell properties of S-BMMSCs, we collected SSEA4-positive
S-BMMSCs and assessed their proliferation rate by BrdU
incorporation. We found that S-BMMSCs had a signifi-
cantly elevated BrdU uptake rate compared to regular
BMMSCs (Figure 1D). In addition, we used a continuous
cell culture assay to indicate that SSEA4-positive S-
BMMSCs acquired a significantly increased number of
population doublings (Figure 1E). These data imply that S-
BMMSCs are distinct from regular BMMSCs in terms of
attachment, proliferation, and self-renewal.
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Figure 1 Identification of suspension BMMSCs (S-BMMSCs). (A) Hypothetical model indicates that bone marrow all nucleated cells (ANCs)
were seeded at 15 × 106 into 100 mm culture dishes and incubated for two days at 37°C with 5% CO2, and subsequently non-attached cells
from culture suspension were transplanted into immunocompromised mice subcutaneously using hydroxyapatite tricalcium phosphate (HA) as a
carrier for eight weeks. Newly formed bone (B) by osteoblasts (arrow heads) and associated connective tissue (C) were detected in this non-
attached cell transplants by H & E staining. Bar = 100 μm. (B) Hypothetical model of isolating S-BMMSCs. BMMSCs usually attach on culture
dishes within two days; however, a small portion of BMMSCs in ANCs failed to attach to the dishes and remained in the suspension. The
suspensions containing putative non-attached BMMSCs were collected and transferred to the extracellular matrix (ECM) coated dish with
generating single colony clusters (CFU-F). These ECM-attached BMMSCs (S-BMMSCs) were sub-cultured on regular plastic culture dishes for
additional experiments. (C) The number of plastic attached CFU-F from ANCs (1.5 × 106 cells) is more than seven-fold higher than that derived
from BMMSC-ECM adherent S-BMMSCs. (D) Proliferation rates of S-BMMSCs and BMMSCs were assessed by BrdU incorporation for 24 hours. The
percentage of positive cells is significantly increased in S-BMMSCs when compared to BMMSCs. (E) S-BMMSCs exhibit a significant increase in
population doublings when compared to BMMSCs. The results are representative of five independent experiments. Scale bars = 50 μm.
***P <0.001. The graph bar represents mean ± SD. BMMSCs, bone marrow mesenchymal stem cells; BrdU, bromodeoxyuridine; S-BMMSCs,
BMMSCs in suspension; SD, standard deviation.
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To examine the multipotent differentiation potential,
we showed that S-BMMSCs are analogous to BMMSCs
in their expression of alkaline phosphatase (ALP),
mineralized nodule accumulation under the osteogenic
inductive cultures, and bone regeneration when trans-
planted into immunocompromised mice using HA/TCP
as a carrier (Figures 2A and 2B). Furthermore, we
showed that S-BMMSCs were similar to regular
BMMSCs in forming Oil red-O positive fat cells under
adipogenic inductive conditions, which was associated
with expression of the adipogenic genes, peroxisome
proliferator-activated receptor gamma 2 (pparg2) and
lipoprotein lipase (lpl) (Figures 2C and 2D). Parallel stu-
dies showed a similar capacity between S-BMMSCs and
regular BMMSCs to differentiate into chondrocytes
under chondrogenic inductive conditions, associated
with the expression of proteoglycan, trichrome positive
collagen, and type II collagen (Figure 2E). Collectively,
these data confirm that S-BMMSCs are a subset of
BMMSCs.
S-BMMSCs express CD34, but are distinct from
hematopoietic stem cells
By flow cytometric analysis, S-BMMSCs expressed
mesenchymal stem cell markers at the same level as
regular BMMSCs (Figure 3A). Interestingly, 23.4% of
S-BMMSCs expressed CD34, a hematopoietic stem cell
(HSC) and endothelial cell marker, whereas 0.2% of
BMMSCs expressed CD34 (Figure 3A). BMMSCs (21.4%)
and S-BMMSCs (31.2%) expressed CD45, another hema-
topoietic marker, at passage 2 (Figure 3A). Both BMMSCs
and S-BMMSCs were negative to CD11b antibody stain-
ing (data not shown), excluding the possibility that
S-BMMSCs are derived from monocyte/macrophage line-
age cells. Importantly, CD34+ S-BMMSCs co-expressed

































































































































Figure 2 Multipotent differentiation of S-BMMSCs. (A) Alizarin Red S and alkaline phosphatase (ALP) staining showed that S-BMMSCs were
similar to regular BMMSCs in osteogenic differentiation in vitro. (B) S-BMMSCs or regular BMMSCs (4 × 106 cells/transplant) were transplanted
into immunocompromised mice using HA/TCP (HA) as a carrier for eight weeks. Bone formation was detected in S-BMMSC and BMMSC
transplants, evidenced by H & E staining. HA, hydroxyapatite tricalcium phosphate; B, bone; M, bone marrow; CT, connective tissue. Bar = 50 μm.
(C-D) S-BMMSCs are capable of forming Oil Red O positive cells (C) and expression of pparg2 and lpl mRNA as seen in regular BMMSCs (D).
Glyceraldehyde 3-phosphate dehydrogenase (gapdh) was used as an internal control. The results are representative of five independent
experiments. Scale bars = 100 μm. (E) Chondrogenic differentiation was assessed by Alcian blue staining for acidic sulfated mucosubstances,
Pollak’s Trichrome staining for collagen, and immunohistochemical staining for collagen type II. S-BMMSCs were able to differentiate into
chondrocytes as observed in regular BMMSCs. Bar = 50 μm. The results are representative of three independent experiments. The graph bar
represents mean ± SD. BMMSCs, bone marrow mesenchymal stem cells; S-BMMSCs, BMMSCs in suspension; SD, standard deviation.
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as evidenced by flow cytometric analysis (Figure 3B). Wes-
tern blot analysis confirmed that S-BMMSCs expressed
CD34, CD73, and CD105 (Figure 3C), and regular
BMMSCs expressed CD73 and CD105 but lacked CD34
expression (Figure 3C). Whole bone marrow cells (BMC)
were used as positive control. S-BMMSCs also showed a
continued expression of CD34 from passage one to five;
however, the expression levels appear reduced after pas-
sage three (Figure 3D). In order to further verify CD34
expression in S-BMMSCs, immunocytostaining analyses
were performed to show co-expression of CD34 with
mesenchymal markers CD73 (Figure 3E) in contrast to
regular BMMSCs that were negative for anti-CD34 anti-
body staining (Figure 3E).
It is generally believed that CD34 expression is asso-
ciated with HSCs and endothelial populations. HSCs
can differentiate into all the blood cell lineages and res-
cue lethally irradiated subjects. Thus, we cultured
S-BMMSCs and regular BMMSCs in hematopoietic dif-
ferentiation medium and determined that these
mesenchymal cells failed to differentiate into a hemato-
poietic cell lineage compare to bone marrow cells that
formed myeloid and erythroid colony forming clusters
(Figure 3F). In addition, CD45-CD34-BMMSCs showed
an ability similar to that of S-BMMSCs in colony form-
ing and expressing surface marker as MSC [see Addi-
tional file 1, Figure S2]. Furthermore, we infused
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Figure 3 S-BMMSCs express CD34. (A) Flow cytometric analysis showed that regular BMMSCs fail to express CD34, but are positive for CD45
antibody staining (21.4%). However, S-BMMSCs express both CD34 (23.4%) and CD45 (31.2%). (B) Flow cytometric analysis also showed that
CD34+ S-BMMSCs were positive for anti CD73 (13.8%) and Oct4 (13.4%) antibody staining. IgG isotype staining groups were used as negative
controls. (C, D) Western blot analysis indicated that S-BMMSCs express CD34 and mesenchymal surface molecules CD73 and CD105. In contrast,
regular BMMSCs only express CD73 and CD105 (C). S-BMMSCs express CD34 at passage one to five (D). b-actin was used as a sample loading
control. BMC, whole bone marrow ANC. (E) Immunocytostaining confirmed that S-BMMSCs are double positive for CD34/CD73 (triangle). Regular
BMMSCs are negative for CD34 antibody staining and only positive for anti CD73 antibody staining. Bar = 100 μm. (F) Both BMMSCs and
S-BMMSCs failed to differentiate into hematopoietic lineage under hematopoietic inductive conditions with EPO (upper panel) or without EPO
(lower panel). Whole bone marrow cells and lineage negative cells were used as positive (yellow arrowheads) control. Bar = 100 μm. ANC, all
nucleated cells; BMMSCs, bone marrow mesenchymal stem cells; EPO, erythropoietin; S-BMMSCs, BMMSCs in suspension.
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mice and found that S-BMMSCs, but not regular
BMMSCs, could extend the lifespan of lethally irradiated
mice [see Additional file 1, Figure S3]. However,
S-BMMSCs failed to rescue lethally irradiated mice, as
shown in the whole bone marrow cell group [see Addi-
tional file 1, Figure S3]. These data provid further evi-
dence that CD34 expression in S-BMMSCs is not due
to HSC contamination.
S-BMMSCs transplantation ameliorates multiple organ
dysfunctions in MRL/lpr mice
Since the immunomodulation property of MSCs is one of
the essential factors for MSC characterization, allogenic
S-BMMSC transplantation into MRL/lpr mice was per-
formed (Figure 4A). Two weeks after transplantation,
both S-BMMSCs and BMMSCs were capable of amelior-
ating SLE-induced glomerular basal membrane disorder
(yellow arrow, Figure 4B) and reducing the urine protein
level (Figure 4C). It appeared that S-BMMSCs were
superior compared to BMMSCs in terms of reducing the
overall urine protein levels (Figure 4C). As expected,
MRL/lpr mice showed remarkably increased levels of
autoantibodies, including anti-double strand DNA
(dsDNA) IgG and IgM antibodies (Figures 4D and 4E)
and anti-nuclear antibody (ANA; Figure 4F) in the per-
ipheral blood serum. Although S-BMMSC and BMMSC
infusion showed significantly decreased serum levels of
anti-dsDNA IgG, IgM antibodies and ANA in peripheral
blood (Figures 4D-F), S-BMMSCs showed a superior
therapeutic effect in reducing anti-dsDNA IgG antibody
and ANA levels when compared to BMMSCs (Figures
4D and 4F). Additionally, decreased serum albumin levels
in MRL/lpr mice were recovered by S-BMMSC and
BMMSC infusion (Figure 4G) but S-BMMSC treatment
resulted in a more significant recovery than BMMSC
treatment (Figure 4G). Next, flow cytometric analysis
revealed that S-BMMSC showed more effectiveness in
recovering the decreased level of CD4+CD25+Foxp3+
Tregs and increased the number of CD4+IL17+IFNg- T-
lymphocytes (Th17 cells) in peripheral blood when com-
pared to BMMSCs (Figures 4H, 4I). In addition, highly
passaged mouse S-BMMSCs failed to inhibit Th17 differ-
entiation in vitro (data not shown) suggesting that mouse
S-BMMSCs probably lose their immunomodulation prop-
erty under long culture expansion.
Furthermore, we showed that S-BMMSCs were super-
ior to BMMSCs in terms of reducing increased numbers
of tartrate-resistant acid phosphatase (TRAP) positive
osteoclasts in the distal femur epiphysis of MRL/lpr mice
[see Additional file 1, Figure S4A], elevated serum levels
of sRANKL, a critical factor for osteoclastogenesis [see
Additional file 1, Figure S4B] and bone resorption marker
CTX [see Additional file 1, Figure S4C]. These data
suggest that S-BMMSCs exhibit a superior therapeutic
effect for SLE disorders compared to regular BMMSCs.
S-BMMSCs possess superior immunomodulatory functions
via high nitric oxide (NO) production
Recently, immunomodulatory properties were identified
as an important stem cell characteristic of BMMSCs,
leading to the utilization of systemic infused BMMSCs to
treat a variety of immune diseases [19-21]. Here, we
found that S-BMMSCs exhibited a significantly increased
capacity for NO production compared to regular
BMMSCs when treated with IFNg and IL-1b (Figure 5A).
It is known that NO plays a critical role in BMMSC-
mediated immunosuppression [see Additional file 1, Fig-
ures S5A-F] [29]. Therefore, we assessed the functional
role of high NO production in S-BMMSC-associated
immunomodulatory properties. Spleen (SP) cells were
activated by anti-CD3 and anti-CD28 antibodies for three
days and then co-cultured with S-BMMSCs or regular
BMMSCs in the presence of the general NOS inhibitor,
L-NMMA or the iNOS inhibitor, 1400 W, using a Trans-
well culture system. The efficacy of L-NMMA and 1400
W to inhibit NO production in BMMSCs was verified
[see Additional file 1, Figures S6A and 6B]. Although
both S-BMMSCs and regular BMMSCs were capable of
inhibiting cell viability of activated SP cells, S-BMMSCs
showed a marked inhibition of SP cell viability over that
of regular BMMSCs (Figure 5B). Moreover, both
BMMSCs and S-BMMSCs induced SP cell apoptosis (Fig-
ure 5C). However, S-BMMSCs showed an elevated capa-
city in inducing activated SP cell apoptosis compared to
regular BMMSCs (Figure 5C). Interestingly, when L-
NMMA and 1400 W were added to the cultures, the
number of apoptotic SP cells was significantly reduced in
both S-BMMSC and regular BMMSC groups (Figure 5D
and 5E). These in vitro experimental data suggested that
NO production is an essential factor for BMMSC-
mediated immunomodulation.
Since up-regulation of CD4+CD25+Foxp3+ Tregs is
required for immunotolerance [30], we tested Tregs up-
regulation property of S-BMMSCs and BMMSCs in an in
vitro co-culture system. When naïve-T-cells were co-
cultured with S-BMMSCs or regular BMMSCs in the
presence of IL-2 and TGF-b1, S-BMMSCs showed a sig-
nificant up-regulation of Treg levels compared to regular
BMMSCs (Figure 5F). Both L-NMMA and 1400 W were
able to inhibit BMMSC- and S-BMMSC-induced up-reg-
ulation of Tregs, as shown by flow cytometric analysis
(Figures 5G and 5H). Interestingly, the regulation effect
on Tregs was more significant in the S-BMMSC group
compared to the BMMSC group (Figure 5G and 5H).
Moreover, both BMMSCs and S-BMMSCs could inhibit
differentiation of Th17 in vitro, with a more prominent
Akiyama et al. Stem Cell Research & Therapy 2012, 3:40
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effect observed with S-BMMSC (Figure 5I). These inhibi-
tions of Th17 differentiation were abolished by L-NMMA
(Figure 5J) and 1400 W (Figure 5K). These data further
verified the functional role of NO in S-BMMSC-induced
immunomodulatory effect.
In order to identify whether there are functional endo-
genous S-BMMSCs, we used fluorescence activated cell
sorting (FACS) to isolate CD34 and CD73 double-posi-
tive cells from bone marrow ANCs which resulted in
the recovery of 3.77% double-positive cells [see Addi-
tional file 1, Figure S7A]. These CD34 and CD73
double-positive cells exhibited mesenchymal stem cell
characteristics, including the capacity to form single col-
ony clusters of fibroblast-like cells [see Additional file 1,
Figure S7B], which could differentiate into osteogenic
cells in vitro [see Additional file 1, Figure S7C]. These
data indicated the feasibility of this approach to isolate
S-BMMSC-like cells directly from bone marrow. We
found that CD34+/CD73+ BMMSCs were analogous to
S-BMMSCs in terms of having higher levels of NO pro-
duction when compared to regular BMMSCs [see Addi-
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Figure 4 S-BMMSCs showed superior therapeutic effect on SLE-like MRL/lpr mice. (A) Schema of BMMSC transplantation into MRL/lpr mice.
(B) S-BMMSC and BMMSC treatment recover basal membrane disorder and mesangium cell over-growth in glomerular (G) (H&E staining).
(C) S-BMMSC and BMMSC transplantation could reduce urine protein levels at two weeks post transplantation compared to the MRL/lpr group.
S-BMMSCs offered a more significant reduction compared to BMMSCs. (D, E) The serum levels of anti-dsDNA IgG and IgM antibodies were
significantly increased in MRL/lpr mice compared to controls (C3H). S-BMMSC and BMMSC treatments could reduce antibody levels but
S-BMMSCs showed a superior treatment effect than BMMSC in reducing anti-dsDNA IgG antibody (D). (F) S-BMMSC and BMMSC treatments
could reduce increased levels of anti nuclear antibody (ANA) in MRL/lpr mice. S-BMMSC showed a better effect in ANA reduction compared to
BMMSC. (G) S-BMMSC and BMMSC treatments could increase the albumin level in MRL/lpr mice, which was decreased in controls. S-BMMSC
treatments were more effective in elevating the albumin level compared to BMMSC treatment. (H) Flow cytometric analysis showed a reduced
number of Tregs in MRL/lpr peripheral blood compared to control. BMMSC and S-BMMSC treatments elevated the number of Tregs. S-BMMSCs
induced a more significant elevation of the Tregs level than BMMSCs. (I) Flow cytometric analysis showed an increased number of Th17 in
MRL/lpr mice peripheral blood compared to control. Th17 were markedly decreased in BMMSC and S-BMMSC treated groups. S-BMMSC
treatment induced a more significant reduction of Th17 cells than treatment with BMMSCs. *P <0.05; ** P <0.01; ***P <0.001. The graph bar
represents mean ± SD. BMMSCs, bone marrow mesenchymal stem cells; Ig, immunoglobulin; S-BMMSCs, BMMSCs in suspension; SD, standard
deviation; SLE, systemic lupus erythematosus; Tregs, regulatory T cells.
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protein, serum anti-dsDNA IgG and IgM antibodies in
MRL/lpr mice (data not shown). These data indicate
that endogenous S-BMMSCs could be isolated from
bone marrow using CD34 and CD73 antibodies double
sorting.
Additionally, we used the same BMMSC-ECM isola-
tion approach to reveal the existence of human S-
BMMSCs (hS-BMMSC) that possess stem cell properties
including multipotent differentiation and self-renewal
but lack expression of CD34 (data not shown). hS-
BMMSCs showed elevated NO and kynurenine produc-
tion which indicate high indoleamine 2,3-dioxygenase
(IDO) activity when compared to regular BMMSCs [see
Additional file 1, Figures S8A-C]. Thus, when activated
T cells were co-cultured with hS-BMMSCs, AnnexinV-7
aminoactinomycinD (7AAD) double positive apoptotic
SP cells were significantly elevated compared to

































































































































































































































Figure 5 S-BMMSCs show up-regulated immunomodulatory properties through nitric oxide (NO) production. (A) NO levels in
the supernatant of S-BMMSC and BMMSC culture were significantly higher in the INF-g/IL-1b treated S-BMMSC group than in BMMSCs. (B-C)
S-BMMSCs showed a significant reduction in the cell viability of activated SP cells compared to the cells cultured without BMMSCs (SP cell) and
with BMMSCs (B). Both BMMSCs and S-BMMSCs showed a significantly increased rate of SP cell apoptosis compared to the SP cell only group
but S-BMMSCs could induce higher SP cell apoptosis (C). (D-E) The induction of SP cell apoptosis by BMMSCs or S-BMMSCs was abolished in
general NOS inhibitor L-NMMA-treated (D) and iNOS specific inhibitor 1400 W-treated (E) group. (F-H) Activated CD4+CD25- T-cells and
S-BMMSCs or BMMSCs were co-cultured in the presence of TGFb1 and IL-2 with or without NOS inhibitor for three days. The floating cells were
stained for CD4+CD25+FoxP3+ regulatory T cells (Tregs). Both BMMSCs and S-BMMSC up-regulated Tregs but S-BMMSCs showed a significant
effect in up-regulating Tregs. (F). Interestingly, L-NMMA and 1400 W treatments resulted in an abolishing of S-BMMSC-induced up-regulation of
Tregs (G, H). (I) BMMSCs and S-BMMSCs could inhibit Th17 differentiation in vitro. S-BMMSC could inhibit it more effectively. (J, K) L-NMMA (J) or
1400 W (K) could abolish the inhibition of Th17 differentiation by BMMSCs or S-BMMSCs. The results are representative of at least three
independent experiments. *P <0.05; **P <0.01; ***P <0.001. The graph bar represents mean ± SD. BMMSCs, bone marrow mesenchymal stem
cells; iNOS, inducible nitric oxide synthase; L-NMMA, L-NG-monomethyl-arginine; NOS, nitric oxide synthase; S-BMMSCs, BMMSCs in suspension;
SD, standard deviation; SP, spleen; Tregs, regulatory T cells.
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Discussion
Adherent BMMSCs are able to proliferate and undergo
osteogenic differentiation, providing the first evidence of
CFU-F as precursors for osteoblastic lineage [25]. For
over a few decades, the adherent CFU-F assay has been
used as an effective approach to identify and select
BMMSCs. In the current study, we showed that the
adherent CFU-F assay collects the majority of clono-
genic BMMSCs, but a subpopulation of BMMSCs is sus-
tained in the culture suspension. This newly identified
subpopulation of BMMSCs may be lost in the standard
CFU-F assay for BMMSC isolation.
Due to the heterogeneity of the BMMSCs, there is no
single, unique marker allowing for BMMSC isolation,
rather an array of cell molecules are utilized to profile
BMMSCs. It is widely accepted that BMMSCs express
SH2 (CD105), SH3/SH4 (CD73), integrin b1 (CD29),
CD44, Thy-1 (CD90), CD71, vascular cell adhesion
molecule-1 (CD106), activated leukocyte cell adhesion
molecule (CD166), STRO-1, GD2, and melanoma cell
adhesion molecule (CD146) [5,7-13,31,32]. Nevertheless,
it is believed that BMMSCs lack expression of hemato-
poietic surface molecules including CD34, integrin aM
(CD11b) and CD14. However, recent studies have
implied that mouse BMMSCs might express the hema-
topoietic surface molecules, CD45 [28] and CD34 [33].
To ensure purity of S-BMMSCs, we used immune FACS
to collect SSEA4+ S-BMMSCs for proliferation and dif-
ferentiation assays in this study. Interestingly, previous
experimental evidence appeared to support a notion
that HSCs are capable of differentiating into mesenchy-
mal cells [34] and osteoblastic lineage in vivo [35]. Thus,
it is critical to clarify whether BMMSCs express hemato-
poietic associated surface molecules.
In this study, we have identified a novel subset of S-
BMMSCs that failed to form adherent CFU-F in regular
culture dishes, but were capable of adhering on
mesenchymal stem cell-produced ECM and differentiat-
ing into osteoblasts, adipocytes and chondrocytes from
both C3H/HeJ and C57BL/6J mice. S-BMMSCs co-
expressed the HSC marker CD34 with the MSC markers
CD73 and Oct4, excluding the potential of HSC con-
tamination. Furthermore, S-BMMSCs were found to be
distinct from HSC because they lacked the ability to dif-
ferentiate into hematopoietic cell lineages in vitro and
failed to rescue lethally-irradiated mice. The mechanism
that may contribute to the up-regulated immunomodu-
latory function was associated with high NO production
in S-BMMSCs and a NO-driven high Tregs level [36].
NO is a gaseous biological mediator with important
roles in affecting T cell function [37].
This is the reason that S-BMMSCs showed a superior
therapeutic effect in treating SLE mice.
One successful approach is to isolate cells that express
specific molecules on their cell surfaces using monoclo-
nal antibodies and cell sorting technologies. Enriched
populations of BMMSCs have been isolated from
human bone marrow aspirates using a STRO-1 mono-
clonal antibody in conjunction with antibodies against
VCAM-1/CD106 [32], CD146 [11], low affinity nerve
growth factor receptor/CD271, PDGR-R, EGF-R and
IGF-1-R [38], fibroblast cell marker/D7-Fib [39] and
integrin alpha 1/CD49a [40]. A more recent study has
also identified molecules co-expressed by a CD271+
mesenchymal stem cell population including platelet
derived growth factor receptor-b (CD140b), human epi-
dermal growth factor 2/ErbB2 (CD340) and frizzled-9
(CD349) [41]. Further cell separation based upon multi-
parameter FACS identified a population of proposed
mouse mesenchymal precursors with the composite
phenotype Lin-CD45-CD31-Sca-1+ [42]. Another recent
study also identified and characterized an alternate
population of primitive mesenchymal cells derived from
adult mouse bone marrow, based upon their expression
of the SSEA-1 [43]. All approaches used for BMMSC
purification and isolation will undergo ex vivo expansion
to enrich cell numbers for tissue regeneration or sys-
temic therapies by plastic adherent assay. In addition to
identifying a novel sub-population of BMMSCs that pos-
sess enhanced immunomodulatory properties when
compared to regular BMMSCs, we showed that CD34
+/CD73+ BMMSCs could be isolated directly from
whole bone marrow and that CD34+/CD73+ BMMSCs
are endogenous S-BMMSCs with higher NO production,
and are superior in treating SLE-like mice when com-
pared to regular BMMSCs.
Recently, non-adherent bone marrow cells (NA-
BMCs) were identified [44,45]. The NA-BMSCs could
be expanded in suspension and gave rise to multiple
mesenchymal phenotypes, including osteoblasts, chon-
drocytes, and adipocytes in vitro, suggesting the pre-
sence of non-adherent BMMSCs in primary CFU-F
cultures [45]. Although it has been reported that the
NA-BMCs can rescue lethally-irradiated mouse recipi-
ents, our data indicated that S-BMMSCs only showed
improved survival lifespan without a complete rescue
of lethally-irradiated mice, compared to whole bone
marrow transplantation. While the mechanism of S-
BMMSC-mediated lifespan extension in lethally-irra-
diated mice is unknown, it is possible that S-BMMSCs
have a more active interplay with hematopoietic cells
than regular BMMSCs. It has been reported that granu-
locyte colony stimulating factor might promote
BMMSCs into the circulation in humans [46], suggest-
ing that non-attached BMMSCs may exist in vivo for
specific functional needs. Added evidence indicated that
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osteocalcin-positive cells in circulation were able to dif-
ferentiate into osteoblastic cells when cultured in the
presence of TGFb [47]. However, it is unknown whether
S-BMMSCs are associated with circulating mesenchymal
stem cells initially identified in mice, and this is very
rare in humans.
Conclusions
A new subset of BMMSCs (S-BMMSCs) which failed to
adhere to culture dishes possesses similar stem cell
properties as those seen in BMMSCs, including CFU-F,
stem cell markers, osto-, adipo-, and chondro-genic dif-
ferentiation. However, S-BMMSC showed distinct fea-
tures including expression of CD34 and a superior
immunomodulation property through high NO produc-
tion. These findings suggest that it is feasible to improve
immunotherapy by identifying new subset BMMSCs.
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